← Oncology Approval Tracker

FDA DECISION ·

Darzalex Faspro + bortezomib + thalidomide + dexamethasone

daratumumab and hyaluronidase-fihj with bortezomib, thalidomide and dexamethasone · Janssen Biotech

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation.

LAMPGEN ANALYSIS

Why it matters

The supplemental action adds subcutaneous daratumumab to a transplant-eligible induction regimen.

What research teams should watch

Verify transplant eligibility, administration route and coordination between induction and transplant teams.

PRIMARY RECORDS

Sources